EE149: Predicting the Population Budget Impact of Current and New Listings for Colorectal Cancer: The PRIMCAT-CRC Model

EE308: Real-World Treatment Patterns and Costs in Relapsed and Refractory Diffuse Large B-Cell Lymphoma in the United States

EE359: US Cost-Effectiveness of Chimeric Antigen Receptor T-Cell (CAR T) Therapy for Patients with Relapsed or Refractory Large B-Cell Lymphoma (R/R LBCL), Considering Infusion Setting and Payor Claims Data

EE437: Healthcare Resource Utilization and Costs in Patients with Multiple Myeloma Who Received 1 to 3 Prior Lines of Therapy, Including a Proteasome Inhibitor, an Immunomodulatory Drug, and Exposed to (AND DISCONTINUED) Lenalidomide in the United States

HSD101: Lack of Concordance between Real-World Treatment Patterns and Clinical Guideline Recommendations For Metastatic Hormone-Sensitive Prostate Cancer (MHSPC) Patients